Advanced search    

Search: authors:"Fabrizia Mariotti"

3 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers Fabrizia ... approved publication: Dr Richard Russell Fabrizia Mariotti,1 Mirco Govoni,1 Germano Lucci,1 Debora Santoro,1 Marie Anna Nandeuil2 1Global Clinical Development, Chiesi Farmaceutici SpA

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study Dave Singh,1 Mario Scuri,2 Sara Collarini,2 Stefano Vezzoli,2 Fabrizia Mariotti,2 Annamaria Muraro,2 Daniela Acerbi2

A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug–Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993

Background and Objectives CHF 5993 is an extrafine ‘triple therapy’ combination of the long-acting muscarinic antagonist glycopyrronium bromide (GB), the long-acting β2-agonist formoterol fumarate (FF), and the inhaled corticosteroid beclometasone dipropionate (BDP). It is in development for chronic obstructive pulmonary disease and asthma delivered via pressurised metered-dose...